Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Targeted Antibiotics Could Get Limited Data Approval Option From FDA

Executive Summary

Achaogen has designed a registration program with a single Phase III study for its next-generation aminoglycoside, plazomicin, to treat serious infections due to carbapenem-resistant Enterobacteriaceae, in what could be an interesting test for potential modifications to the standard approval pathway.

You may also be interested in...



Actavis Counting On Strong Product Line Depth For Avycaz Launch

The specialty pharma will take advantage of its presence in antibiotics to launch its third FDA-approved antibiotic for hard-to-treat infections before the end of the second quarter.

Actavis’ Avycaz Approval Shows How FDA Handles Limited-Data, Limited-Use Antibiotic

FDA grants approval to two of three indications for gram-negative antibiotic based on Phase II data but follows its advisors in rejecting a third indication that came without human data, offering hints of what the limitations and possibilities of a formal limited population antibiotic approval pathway might look like.

Actavis Avycaz Approval Shows How FDA Handles Limited-Data, Limited-Use Antibiotic

FDA grants approval to two of three indications for gram-negative antibiotic based on Phase II data, but follows it advisors in rejecting a third indication that came without human data, offering hints of what the limitations and possibilities of a formal limited population antibiotic approval pathway might be.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS055109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel